Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Pharmacotherapy|October 28, 2009
Bendamustine: a new treatment option for chronic lymphocytic leukemiaAshley E Glode, Anthony JarkowskiJournal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 31, 2019
Apalutamide: A new agent in the management of prostate cancerMegan B May, Ashley E GlodeCancer Management and Research|June 9, 2016
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemeticsMegan Brafford May, Ashley E GlodePharmacotherapy|November 19, 2016
Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control CostsAshley E Glode, Megan Brafford MayAmerican Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 13, 2021
Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatmentAshley E Glode, Megan B MayJournal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 17, 2022
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphomaJames A Davis, Abigail Shockley, Ashley E GlodeJournal of the Advanced Practitioner in Oncology|July 17, 2019
Gemtuzumab Ozogamicin: Back AgainChris Selby, Lisa R Yacko, Ashley E GlodeJournal of the Advanced Practitioner in Oncology|January 4, 2021
A Review of PI3K Inhibitors in B-Cell MalignanciesLaura Cannon, Emmeline C Academia, Ashley E GlodeJournal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 8, 2020
Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical centerMelissa Gamble, Elisabeth Carroll, Garth C Wright, et al.Expert Opinion on Investigational Drugs|April 4, 2018
Ublituximab for the treatment of CD20 positive B-cell malignanciesHani M Babiker, Ashley E Glode, Laurence S Cooke, et al.Pageof 2